Ra Medical Systems, Inc. specializes in developing and marketing medical devices for dermatological and vascular conditions, particularly its DABRA laser system used for treating peripheral artery disease. The company operates primarily in the United States and is positioned in a niche market with high gross margins but struggles with operational profitability.
Ra Medical generates revenue through the sale of its proprietary DABRA laser systems and associated consumables. The high gross margin of 92.3% indicates strong pricing power, although the company faces challenges in scaling operations due to significant operating losses.
Regulatory approvals for new devices or indications
Sales growth in the DABRA system and consumables
Partnerships or collaborations with larger medical device companies
Market adoption rates in the vascular treatment sector
Technological disruption from new treatment modalities
Regulatory changes impacting device approval processes
Emerging competitors with innovative vascular treatment solutions
Price competition from established medical device manufacturers
High operational losses leading to cash burn
Liquidity risks due to low current ratio
moderate - The demand for medical devices can be somewhat insulated from economic downturns, but elective procedures may decline during recessions.
Higher interest rates could increase financing costs for the company, impacting its ability to invest in growth and potentially leading to lower valuations.
minimal - The company has a manageable debt-to-equity ratio of 1.25, but its current ratio of 0.06 indicates liquidity concerns.
growth - Investors looking for high-risk, high-reward opportunities in the medical device space.
high - The stock has exhibited significant volatility, with a 1-year return of -91.3%.